Advertisement
Collaboration › Details
Aimmune Therapeutics–Credit Suisse: investor conference, 201811 supply service Aimmune presents at Credit Suisse Annual Healthcare Conference 2018
Period | 2018-11-14 | |
Partner, 1st | Aimmune Therapeutics Inc. (Nasdaq: AIMT) | |
Group | Nestlé (Group) | |
Partner, 2nd | Credit Suisse Securities (USA) LLC | |
Group | UBS (Group) | |
Product | Credit Suisse Annual Healthcare Conference 2018 Scottsdale | |
Product 2 | CODIT™ (Characterized Oral Desensitization ImmunoTherapy) | |
Person | Dallas, Jayson (Aimmune Therapeutics 201806– CEO before Ultragenyx + Roche + Novartis + Pfizer + P&G Pharma) | |
Aimmune Therapeutics, Inc.. (11/1/18). "Press Release: Aimmune Therapeutics to Participate in Upcoming Investor Conferences". Brisbane, CA.
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that members of senior management will participate in the following investor conferences:
> Stifel 2018 Healthcare Conference (November 13, New York): Fireside chat with Eric Bjerkholt, CFO, starting at 3:30 p.m. ET
> 27th Annual Credit Suisse Healthcare Conference (November 14, Scottsdale, AZ): Fireside chat with Jayson Dallas, M.D., President and CEO, starting at 8:35 a.m. MT
> Jefferies 2018 London Healthcare Conference (November 15, London): 1x1 meetings with Eric Bjerkholt, CFO, and Sue Barrowcliffe, General Manager of Europe
> Piper Jaffray 30th Annual Healthcare Conference (November 28, New York): Fireside chat with Jayson Dallas, M.D., President and CEO, starting at 3:30 p.m. ET
> Mizuho Conference (December 3, New York): 1x1 meetings with Eric Bjerkholt, CFO
Live webcasts of the audio portions of the fireside chats will be accessible on the Events page under the Investor Relations section of the Aimmune website at www.aimmune.com. Replays of the webcasts will be available for at least 30 days following each webcast.
About Aimmune Therapeutics
Aimmune Therapeutics, Inc., is a biopharmaceutical company developing treatments for life-threatening food allergies. The company’s Characterized Oral Desensitization ImmunoTherapy (CODIT™) approach is intended to provide meaningful levels of protection against allergic reactions resulting from accidental exposure to food allergens by desensitizing patients with defined, precise amounts of key allergens. Aimmune’s first investigational biologic product using CODIT™, AR101 for the treatment of peanut allergy, has received the FDA’s Breakthrough Therapy Designation for the desensitization of peanut-allergic patients 4–17 years of age. Aimmune plans to submit regulatory filings for marketing approval of AR101 in the United States and Europe based on data from the pivotal Phase 3 PALISADE clinical trial of AR101, which in 4–17-year-old subjects met its primary and key secondary endpoints, and additional ongoing and completed AR101 clinical trials. For more information, please see www.aimmune.com.
Aimmune Therapeutics, Inc.
Investors
Laura Hansen, Ph.D., (650) 396-3814 or
lhansen@aimmune.com
or
Media
Alison Marquiss, (650) 376-5583
amarquiss@aimmune.com
Record changed: 2018-11-25 |
Advertisement
More documents for Nestlé (Group)
- [1] Recipharm AB. (11/21/23). "Press Release: Marc Funk to Transition to Recipharm's Board of Directors; Greg Behar Appointed New CEO; Inhaled Business to Standalone in 2024"....
- [2] Enterome S.A.. (7/18/22). "Press Release: Enterome Signs Major Strategic R&D Collaboration with Nestlé Health Science to Develop and Commercialize New AllerMimics and EndoMimics Immunotherapies for Food Allergies and Inflammatory Bowel Disease". Paris....
- [3] Seres Therapeutics, Inc.. (7/1/21). "Press Release: Seres Therapeutics, Nestlé Health Science Announce SER-109 Co-Commercialization License Agreement". Cambridge, MA & Lausanne....
- [4] ECBF Management GmbH. (12/15/20). "Press Release: The European Circular Bioeconomy Fund Welcomes Nestlé as an Investor to Accelerate Sustainable Innovation in Europe". Luxembourg....
- [5] Aimmune Therapeutics, Inc.. (8/31/20). "Press Release: Aimmune Therapeutics Enters Definitive Agreement with Sociétés des Produits Nestlé S.A., Part of Nestlé Health Science". Brisbane, CA....
- [6] Seres Therapeutics, Inc.. (8/17/20). "Press Release: Seres Therapeutics, Inc. Announces Closing of Public Offerings of 12,075,000 Shares of Common Stock". Cambridge, MA....
- [7] Aimmune Therapeutics, Inc.. (2/5/20). "Press Release: Aimmune Therapeutics Announces Additional $200 Million Equity Investment by Nestlé Health Science". Brisbane, CA....
- [8] Aimmune Therapeutics, Inc.. (3/25/19). "Press Release: European Phase 3 Trial of Aimmune Therapeutics’ AR101 Meets Primary Endpoint. Company Intends to Submit European MAA in Mid-2019". Brisbane, CA....
- [9] Seres Therapeutics, Inc.. (3/6/19). "Press Release: Seres Therapeutics Reports Fourth Quarter and Full Year Financial Results and Provides Operational Updates". Cambridge, MA....
- [10] Aimmune Therapeutics, Inc.. (2/28/19). "Press Release: Aimmune Therapeutics Announces Fourth Quarter and Full Year 2018 Financial Results and Provides Recent Operational Highlights". Brisbane, CA....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top